Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 410-415

  Wakelee, H A ^a   Dahlberg, S E ^b   Brahmer, J R ^c   Schiller, J H ^d   Perry, M C ^e   Langer, C J ^f   Sandler, A B ^g   Belani, C P ^h   Johnson, D H ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Age sex interactions; Bevacizumab; Chemotherapy; NSCLC; Prognostic factors; Sex gender differences

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEX FACTORS;

EID: 84862815339     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.006     Document Type: Article

References (35)

1. Edmonson J.H., Lagakos S.W., Selawry O.S., Perlia C.P., Bennett J.M., Muggia F.M., et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1976, 60:925-932.
2. Radzikowska E., Glaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002, 13:1087-1093.
3. Visbal A.L., Williams B.A., Nichols F.C., Marks R.S., Jett J.R., Aubry M.C., et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004, 78:209-215. discussion 215.
4. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986, 4:702-709.
5. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991, 9:1618-1626.
6. Wakelee H.A., Wang W., Schiller J.H., Langer C.J., Sandler A.B., Belani C.P., et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group Trial 1594. J Thorac Oncol 2006, 1:441-446.
7. Albain K.S., Unger J., Gotay C.C., Davies A.M., Edelman M., Herbst R.S., et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 2007, 25:396s. [Abstr#7549].
8. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
9. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
10. Langer C.J., Vangel M., Schiller J., Harrington D.P., Sandler A., Belani C.P., et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003, 22:639. [Abstract #2571].
11. Mosselman S., Polman J., Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392:49-53.
12. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002, 62:2141-2150.
13. Mollerup S., Jorgensen K., Berge G., Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 2002, 37:153-159.
14. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006, 24:59-63.
15. Chlebowski R.T., Schwartz A.G., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E., et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post hoc analysis of a randomised controlled trial. Lancet 2009, 374:1243-1251.
16. Chlebowski R.T., Anderson G.L., Manson J.E., Schwartz A.G., Wakelee H., Gass M., et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010, 102:1413-1421.
17. Shweiki D., Itin A., Neufeld G., Gitay-Goren H., Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993, 91:2235-2243.
18. Hyder S.M., Nawaz Z., Chiappetta C., Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000, 60:3183-3190.
19. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000, 92:1764-1772.
20. Spitz M.R., Wei Q., Dong Q., Amos C.I., Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003, 12:689-698.
21. Ryberg D., Hewer A., Phillips D.H., Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994, 54:5801-5803.
22. Mollerup S., Ryberg D., Hewer A., Phillips D.H., Haugen A. Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999, 59:3317-3320.
23. Wisnivesky J.P., Halm E.A. Sex differences in lung cancer survival: do tumors behave differently in elderly women?. J Clin Oncol 2007, 25:1705-1712.
24. Ramalingam S.S., Dahlberg S.E., Langer C.J., Gray R., Belani C.P., Brahmer J.R., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
25. Brahmer J.R., Gray R., Schiller J.H., Perry M., Sandler A., Johnson D.H. ECOG 4599 phase III trial of carboplatin and paclitaxel±bevacizumab: subset analysis of survival by gender. J Clin Oncol 2006, 24:373s. [Abstract #7036].
26. Mueller M.D., Vigne J.L., Minchenko A., Lebovic D.I., Leitman D.C., Taylor R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 2000, 97:10972-10977.
27. Seo K.H., Lee H.S., Jung B., Ko H.M., Choi J.H., Park S.J., et al. Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation. Cancer Res 2004, 64:6482-6488.
28. Heer K., Kumar H., Speirs V., Greenman J., Drew P.J., Fox J.N., et al. Vascular endothelial growth factor in premenopausal women - indicator of the best time for breast cancer surgery?. Br J Cancer 1998, 78:1203-1207.
29. Kusumanto Y.H., Hospers G.A., Sluiter W.J., Dam W.A., Meijer C., Mulder N.H. Circulating vascular endothelial growth factor during the normal menstrual cycle. Anticancer Res 2004, 24:4237-4241.
30. Agrawal R., Prelevic G., Conway G.S., Payne N.N., Ginsburg J., Jacobs H.S. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 2000, 73:56-60.
31. Akkad A., Al-Azzawi F. Changes in serum vascular endothelial growth factor following initiation of estrogen replacement after hysterectomy and oophorectomy. Acta Obstet Gynecol Scand 2001, 80:554-558.
32. Sumino H., Nakamura T., Ichikawa S., Kanda T., Sakamaki T., Sato K., et al. Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia. Atherosclerosis 2000, 148:189-195.
33. Garvin S., Dabrosin C. In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients. BMC Cancer 2008, 8:73.
34. Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res 2005, 11:8036-8041.
35. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407-1412.